IMV News and Press, IMV Inc. From 04/08/22

Combination of MVP-S/CPA and pembrolizumab showed encouraging clinical activity in advanced, metastatic bladder cancer patients, particularly in patients who had received prior immune checkpoint inhibitor therapy The combination treatment was well-tolerated with adverse events...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

IMV Inc. (NASDAQ:IMV) traded at a new 52-week high today of $9.50. So far today approximately 43.7 million shares have been exchanged, as compared to an average 30-day volume of 99,000 shares. IMV Inc is a clinical-stage biopharmaceutical company. The company is engaged in making immunot...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced the Company will present a poster at IMMUNOLOGY™ 2022, the annual meeting ...

IMV Inc. (IMV) Q4 2021 Earnings Conference Call March 17, 2022 08:00 ET Company Participants Joy Bessenger - Senior Vice President, Investor Relations & Corporate Strategy Andrew Hall - Chief Executive Officer Jeremy Graff - Chief Scientific Officer Pierre Labbe - Chief Financial Officer ...

IMV press release (NASDAQ:IMV): FY GAAP EPS of -$0.49 misses by $0.04. As of December 31, 2021, the Company had cash and cash equivalents of $38.6 million, compared to $36.3 million as of December 31, 2020. For further details see: IMV GAAP EPS of -$0.49 misses by $0.04

First patient dosed in VITALIZE Phase 2B trial in relapsed/refractory DLBCL Metastatic bladder cancer cohort data from Phase 2 basket trial to be presented at late-breaking symposium at AACR Phase 2B Avalon trial in advanced ovarian cancer to start in second ...

IDEX, LEN, WSM, PD, CPRX, NBEV, SYN, OTCQX:MRMD, REI, OTCQX:TRSSF, ZTO, ASM, SMTC, GES, LGO, SMTS, BAK, LMB, LFT, EDR, ETON, IMV, PANL For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Wednesday's close

IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Thursday, March 17, 2022, at 8:00 ...

IMV’s DPX technology elicits a coordinated anti-tumor immune response involving natural killer cells in both translational and preclinical studies Clinical data from the Company’s basket study in advanced, metastatic bladder cancer will be presented at the ...